New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:08 EDTCLSNCelsion announces positive results from Phase III HEAT Study of ThermoDox
Celsion announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation, supports the continued clinical development of ThermoDox in a prospective pivotal Phase III Study, subject to regulatory review and agreement. As provided for in the HEAT Study's Special Protocol Assessment, or SPA, agreement with the FDA the Company continues to follow patients for overall survival, the secondary endpoint of the Study. Data from four quarterly reviews of overall survival have been evaluated since the announcement of top line PFS data.
News For CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CLSN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use